化学名称: (E)-4-(((2S,4R)-1-([1,1'-Biphenyl]-4-yl)-5-methoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobut-2-enoic acid
微笑: COC([C@H](C)C[C@H](NC(/C=C/C(O)=O)=O)CC1=CC=C(C=C1)C2=CC=CC=C2)=O
印地语: InChI=1S/C23H27ClO7/c24-18-6-3-14(22-20(27)21(28)23(31-22)19(26)11-25)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21+,22?,23-/m0/s1
A liquid chromatographic method for separation of sacubitril–valsartan and their stereoisomeric impurities
Lu Zhou, Liang Zou, Lili Sun, Hui Zhang, Wenkai Hui and Qiaogen Zou
Anal. Methods, 2018,10, 1046-1053
Quantification of potential genotoxic impurity in sacubitril/valsartan drug substance at ppm level by LC-MS/MS
Ravi Uppala, M.Arthanareeswari, S.Devikala,T.Pushpamalini, J. ArockiaSelvi
Materials Today: Proceedings Volume 14, Part 2, 2019, Pages 640-645
Experimental Design Approach in HPLC Method Development: Application for the Simultaneous Determination of Sacubitril and Valsartan in Presence of Their Impurities and Investigation of Degradation Kinetics
Bahia A. Moussa, Hanaa M. A. Hashem, Marianne A. Mahrouse & Sally T. Mahmoud
Chromatographia volume 81, pages139–156(2018)
Development and validation of a stability indicating UHPLC method for Sacubitril/Valsartan complex in the presence of impurities and degradation products
Pintu Prajapati, Dhara Bhayani, Priti Mehta.
J App Pharm Sci. 2020; 10(2): 97-107